• Explore /
  • Poster
  • / Circulating tumor DNA (ctDNA) in HER2 exon 20 insertion mutations and responses in NSCLC HER2 exon 20 insertion treated with poziotinib.

Circulating tumor DNA (ctDNA) in HER2 exon 20 insertion mutations and responses in NSCLC HER2 exon 20 insertion treated with poziotinib.

Abstract Poster

Authors

null

Arunthi Thiagalingam

Spectrum Pharmaceuticals, Boston, MA

Arunthi Thiagalingam , Sribalaji Lakshmikanthan , Allysia Mak , Scott A. Shell , Sharon Leu , Sophie Sun , Erin Marie Bertino , Eric B. Haura , Rocky Washington , Gajanan Bhat , Francois M. Lebel , John A. Barrett

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Circulating Biomarkers

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 3051)

DOI

10.1200/JCO.2022.40.16_suppl.3051

Abstract #

3051

Poster Bd #

43

Abstract Disclosures

Similar Posters

First Author: Zandong Yang

First Author: Jianwen Qin

Poster

2019 ASCO Annual Meeting

Characterization of 648 non-small cell lung cancer (NSCLC) cases with 28 unique <em>HER2</em> exon 20 insertions.

Characterization of 648 non-small cell lung cancer (NSCLC) cases with 28 unique HER2 exon 20 insertions.

First Author: Sai-Hong Ignatius Ou

First Author: Marcelo Vailati Negrao